Enovis Overview
- Year Founded
-
1995
- Status
-
Public
- Employees
-
7,000
- Stock Symbol
-
ENOV
- Investments
-
41
- Share Price
-
$25.47
- (As of Friday Closing)
Enovis General Information
Description
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
Contact Information
Website
www.enovis.comCorporate Office
- 2711 Centerville Road
- Suite 400
- Wilmington, DE 19808
- United States
Corporate Office
- 2711 Centerville Road
- Suite 400
- Wilmington, DE 19808
- United States
Enovis Timeline
Enovis Stock Performance
As of 20-Nov-2026, Enovis’s stock price is $25.47. Its current market cap is $1.47B with 57.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $25.47 | $26.23 | $16.70 - $31.66 | $1.47B | 57.7M | 1.69M | -$9.22 |
Enovis Financials Summary
As of 30-Sep-2026, Enovis has a trailing 12-month revenue of $2.31B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,412,205 | 2,934,165 | 3,833,709 | 3,493,431 |
| Revenue | 2,306,416 | 2,248,049 | 2,107,623 | 1,707,197 |
| EBITDA | (174,672) | (830,217) | (481,028) | 169,730 |
| Net Income | (527,404) | (1,184,440) | (825,494) | (33,261) |
| Total Assets | 3,735,544 | 3,834,737 | 4,718,777 | 4,509,334 |
| Total Debt | 1,342,530 | 1,379,535 | 1,404,301 | 536,416 |
Enovis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Enovis Comparisons
Industry
Financing
Details
Enovis Competitors (2)
One of Enovis’s 2 competitors is Embla Medical, a Corporation company based in Reykjavik, Iceland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Embla Medical | Corporation | Reykjavik, Iceland | ||||
| Zimmer Biomet Holdings | Corporation | Warsaw, IN |
Enovis Patents
Enovis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260207342-A1 | Total ankle replacement with gradient porous structure | Pending | 17-Jan-2025 | ||
| WO-2026156205-A1 | Total ankle replacement with gradient porous structure | Pending | 17-Jan-2025 | ||
| US-20260207341-A1 | Total ankle replacement with variable constraint articulating surfaces | Pending | 17-Jan-2025 | ||
| WO-2026156204-A1 | Total ankle replacement with variable constraint articulating surfaces | Pending | 17-Jan-2025 | ||
| WO-2026050360-A1 | A stem system for use in total ankle replacement surgery and methods of using the same | Pending | 30-Aug-2024 | A61F2/4202 |
Enovis Signals
Enovis Investments & Acquisitions (41)
Enovis’s most recent deal was a Merger/Acquisition with eCential Robotics for . The deal was made on 01-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| eCential Robotics | 01-Sep-2026 | Merger/Acquisition | Diagnostic Equipment | ||
| ManaMed | 31-Jan-2025 | Corporate Asset Purchase | Therapeutic Devices | ||
| Limacorporate | 03-Jan-2024 | Merger/Acquisition | Therapeutic Devices | ||
| Precision AI Australia | 05-Oct-2023 | Merger/Acquisition | Therapeutic Devices | ||
| SEAL External Fixation | 20-Jul-2023 | Merger/Acquisition | Therapeutic Devices |
Enovis ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
30.24 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Enovis Exits (2)
Enovis’s most recent exit was on 09-Jul-2013 from Clarus Fluid Intelligence. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Clarus Fluid Intelligence | 09-Jul-2013 | Completed |
|
||
| COT-Puritech | 06-Dec-2011 | Merger/Acquisition | Completed |
Enovis Affiliates
Subsidiaries (20)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Precision AI Australia | Fortitude Valley, Australia | 2019 | |
| Surgi-Care Sales | South Burlington, VT | 2019 | |
| Soldex Holdings I | Annapolis Junction, MD | 2019 | |
| Howden Construction Services | Annapolis Junction, MD | 2017 | |
| Clfx Sub Holding | Annapolis Junction, MD | 2017 |
Enovis FAQs
-
When was Enovis founded?
Enovis was founded in 1995.
-
Where is Enovis headquartered?
Enovis is headquartered in Wilmington, DE.
-
What is the size of Enovis?
Enovis has 7,000 total employees.
-
What industry is Enovis in?
Enovis’s primary industry is Therapeutic Devices.
-
Is Enovis a private or public company?
Enovis is a Public company.
-
What is Enovis’s stock symbol?
The ticker symbol for Enovis is ENOV.
-
What is the current stock price of Enovis?
As of 20-Nov-2026 the stock price of Enovis is $25.47.
-
What is the current market cap of Enovis?
The current market capitalization of Enovis is $1.47B.
-
What is Enovis’s current revenue?
The trailing twelve month revenue for Enovis is $2.31B.
-
Who are Enovis’s competitors?
Embla Medical and Zimmer Biomet Holdings are competitors of Enovis.
-
What is Enovis’s annual earnings per share (EPS)?
Enovis’s EPS for 12 months was -$9.22.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process